Research

2020年

  1. Kadoya H, Satoh M, Nishi Y, Kondo M, Wada Y, Sogawa Y, Kidokoro K, Nagasu H, Sasaki T, Kashihara N：Klotho is a novel therapeutic target in peritoneal fibrosis via Wnt signaling inhibition. Nephrol Dial Transplant. 2020 May 1;35(5):773-781.
  2. Nakagawa N, Sofue T, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N：J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Sci Rep. 2020 Apr 30;10(1):7351.
  3. Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N：Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020 Oct 15;15(10):e0240402.
  4. Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N：Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020 Jul 20;15(7):e0236132.
  5. Itano S, Yano Y, Nagasu H, Tomiyama H, Kanegae H, Makino H, Higashi Y, Kobayashi Y, Sogawa Y, Satoh M, Suzuki K, Raymond R.T, Matthew B, George B, and Kashihara N：Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 Nov 3;33(11):1003-1010.
  6. Sogawa Y, Kadoya H, Kashihara N：Drastic change in protein intake may cause a rapid decline of residual renal function after initiation of peritoneal dialysis. Ther Apher Dial. 2020 Dec;24(6):736-738.
  7. Itano S, Kadoya H, Satoh M, Nakamura T, Murase T, Sasaki T, Kanwar YS, Kashihara N：Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice. Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F765-F772.
  8. Tang SCW, Yu X, Chen HC, Kashihara N, Park HC, Liew A, Goh BL, Nazareth MGC, Bunnag S, Tan J, Lun V, Lydia A, Sharma SK, Hoque E, Togtokh A, Ghnaimet M, Jha V：Dialysis Care and Dialysis Funding in Asia. Am J Kidney Dis. 2020 May;75(5):772-781.
  9. Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, Sawanobori T：Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1715-1727.
  10. Kashihara N, Yamasaki Y, Osonoi T, Harada H, Shibagaki Y, Zhao J, Kim H, Yajima T, Sarai N：A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia. Clin Exp Nephrol. 2021 Feb;25(2):140-149.
  11. Katsuno T, Ito Y, Kagami S, Kitamura H, Maruyama S, Shimizu A, Sugiyama H, Sato H, Yokoyama H, Kashihara N：A nationwide cross-sectional analysis of thrombotic microangiopathy in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2020 Sep;24(9):789-797.
  12. Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y：Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2020 Jun;24(6):526-540.
  13. Kashihara N, Nishio T, Osonoi T, Saka Y, Imasawa T, Ohtake T, Mizuno H, Shibagaki Y, Kim H, Yajima T, Sarai N：Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study. Clin Exp Nephrol. 2020 Dec;24(12):1144-1153.
  14. Yokoyama H, Yamamoto R, Imai E, Maruyama S, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Furuichi K, Fujimoto K, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y：Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol. 2020 Oct;24(10):893-909.
  15. Bandaru S, Sano S, Shimizu Y, Seki Y, Okano Y, Sasaki T, Wada H, Otsuki T, Ito T：Impact of heavy rains of 2018 in western Japan: disaster-induced health outcomes among the population of Innoshima Island. Heliyon. 2020 May 25;6(5):e03942.
  16. Kadoya H, Yu　N, Schiessl IM, Riquier-Briston A, Gyarmati G, Desposito D, Kidokoro K, Butler MJ, Jacob CO, Peti-Peterdi J. ：Essential role and therapeutic targeting of the glomerular endothelial glycocalyx in lupus nephritis. JCI Insight. 2020 Oct 2;5(19):e131252.
  17. Yamaguchi R, Kawazoe Y, Shimamoto K, Shinohara E, Tsukamoto T, Shintani-Domoto Y, Nagasu H, Uozaki H, Ushiku T, Nangaku M, Kashihara N, Shimizu A, Nagata M, Ohe K：Glomerular Classification Using Convolutional Neural Networks Based on Defined Annotation Criteria and Concordance Evaluation Among Clinicians. JCI Insight. 2020 Oct 2;5(19):e131252.
  18. Kanda E, Kashihara N, Kohsaka S, Okami S, Yajima T：Clinical and Economic　Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan. Kidney Med. 2020 Oct 17;2(6):742-752.e1.
  19. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Górriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjöström CD, Langkilde AM, Heerspink HJL：The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020 Oct 1;35(10):1700-1711.
  20. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators：Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446.
  21. Kanda E, Epureanu BI, Adachi T, Tsuruta Y, Kikuchi K, Kashihara N, Abe M, Masakane I, Nitta K：Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan. PLoS One. 2020 May 29;15(5):e0233491.
  22. Kashihara N, Kidokoro K, Kanda E：Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms. Curr Opin Nephrol Hypertens. 2020 Jan;29(1):112-118.
  23. Tang SCW, Yu X, Chen HC, Kashihara N, Park HC, Liew A, Goh BL, Nazareth MGC, Bunnag S, Tan J, Lun V, Lydia A, Sharma SK, Hoque E, Togtokh A, Ghnaimet M, Jha V：Dialysis Care and Dialysis Funding in Asia.  Am J Kidney Dis. 2020 May;75(5):772-781.

2019年

  1. Kidokoro K, Cherney D, Bozovic A, Nagasu H, Satoh M, Kanda E, Sasaki T, Kashihara N：Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. Circulation. 2019 Jul 23;140(4):303-315.
  2. Nagasu H, Sogawa Y, Kidokoro K, Itano S, Yamamoto T, Satoh M, Sasaki T, Suzuki T, Yamamoto M, Wigley W Christian, Proksch Joel W, Meyer Colin J, Kashihara N：Bardoxolone methyl analog attenuates proteinuria induced tubular damage by modulating mitochondrial function. FASEB J. 2019 Nov;33(11):12253-12263.
  3. Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T：Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney Int Rep. 2019 May 30;4(9):1248-1260.
  4. Fukui A, Yokoo T, Nangaku M, Kashihara N：New measures against chronic kidney diseases in Japan since 2018.  Clin Exp Nephrol. 2019 Nov;23(11):1263-1271.
  5. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N：The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).  Hypertens Res. 2019 Sep;42(9):1235-1481.
  6. Nakamura S, Hasebe N, Yatabe M, Kishi T, Ishida M, Ichihara A, Node K, Ishimitsu T, Itoh H, Ito M, Ohishi M, Ohkubo T, Kai H, Kashihara N, Kario K, Saitoh S, Tsuchihashi T, Nishiyama A, Higaki J, Miura K, Rakugi H, Kawano Y, Tamura K, Yatabe T, Ohya Y, Ito S：JSH Statement: Asahikawa declaration in promotion of diversity by the Japanese society of hypertension-the JSH Asahikawa declaration. Hypertens Res. 2019 Oct;42(10):1483-1484.
  7. Japanese Society of Nephrology (Kashihara N.)：Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. Clin Exp Nephrol. 2019 Jan;23(1):1-15.
  8. Nagasu A, Mukai T, Iseki M, Kawahara K, Tsuji S, Nagasu H, Ueki Y, Ishihara K, Kashihara N, Morita Y：Sh3bp2 Gain-Of-Function Mutation Ameliorates Lupus Phenotypes in B6.MRL-Faslpr Mice. Cells. 2019 Apr 30;8(5):402.
  9. Uchida A, Kidokoro K, Sogawa Y, Itano S, Nagasu H, Satoh M, Sasaki T, Kashihara N：5-Aminolevulinic acid exerts renoprotective effect via Nrf2 activation in murine rhabdomyolysis-induced acute kidney injury. Nephrology (Carlton). 2019 Jan;24(1):28-38.
  10. Satoh M, Maruhashi T, Yoshida Y, Shibata H：Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronis. Hypertens Res. 2019 Jun;42(6):817-824.
  11. Masaaki Ito, Toshihiko Ishimitsu, Atsuhiro Ichihara, Hiroshi Itoh, Mitsuru Ohishi, Takayoshi Ohkubo, Hisashi Kai, Naoki Kashihara, Kazuomi Kario, Shigeyuki Saitoh, Takuya Tsuchihashi, Satoko Nakamura, Akira Nishiyama, Koichi Node, Naoyuki Hasebe, Jitsuo Higaki, Katsuyuki Miura, Hiromi Rakugi, Kouichi Tamura, Yuhei Kawano, Takashi Yatabe, Yusuke Ohya & Sadayoshi Ito：JSH Statement: Kyoto declaration on hypertension research in Asia. Hypertens Res. 2019 Jun;42(6):759-760.
  12. Butler MJ, Ramnath R, Kadoya H, Desposito D, Riquier-Brison A, Ferguson JK, Onions KL, Ogier AS, ElHegni H, Coward RJ, Welsh GI, Foster RR, Peti-Peterdi J, Satchell SC：Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx. Kidney Int. 2019 Jan;95(1):94-107.

2018年

  1. Hoshino J, Nagai K, Kai H, Saito C, Ito Y, Asahi K, Kondo M, Iseki K, Iseki C, Okada H, Kashihara N, Narita I, Wada T, Combe C, Pisoni RL, Robinson BM, Yamagata K:A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan .The Reach-J CKD cohort study. Clin Exp Nephrol. 22(2):309-317, 2018
  2. Kanda E, Usui T, Kashihara N, Iseki C, Iseki K, Nangaku M:Importance of glomerular filtration rate change as surrogate endpoint for the future incidence of end-stage renal disease in general Japanese population: community-based cohort study. Clin Exp Nephrol. 22(2):318-327, 2018
  3. Porter RS, Murata-Nakamura Y, Nagasu H, Kim HG, Iwase S:Transcriptome Analysis Revealed Impaired cAMP Responsiveness in PHF21A-Deficient Human Cells. Neuroscience. 370(2):170-180, 2018
  4. Komatsu H, Fujimoto S, Maruyama S, Mukoyama M, Sugiyama H, Tsuruya K, Satoh H, Soma J, Yano J, Itano S, Nishino T, Sato T, Narita I, Yokoyama H:Distinict characteristics and outcomes in elderly-onset IgA vasculitis(Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR). PLoS One. 13(5):e0196955, 2018
  5. Doi K, Nishida O, Shigematsu T, Sadahiro T, Itami N, Iseki K, Yuzawa Y, Okada H, Koya D, Kiyomoto H, Shibagaki Y, Matsuda K, Kato A, Hayashi T, Ogawa T, Tsukamoto T, Noiri E, Negi S, Kamei K, Kitayama H, Kashihara N, Moriyama T, Terada Y:Japanese Clinical Practice Guideline for Acute Kidney Injury 2016 Committee. The Japanese clinical practice guideline for acute kidney injury 2016. Clin Exp Nephrol. 22(5):985-1045, 2018
  6. Kanda E, Kashihara N, Matsushita K, Usui T, Okada H, Iseki K, Mikami K, Tanaka T, Wada T, Watada H, Ueki K, Nangaku M: Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease. Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol. 22(6):1446-1475, 2018
  7. Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y:Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol. 22(6):1266-1280, 2018
  8. Usui T, Kanda E, Iseki C, Iseki K, Kashihara N, Nangaku M.:Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population. Nephrology (Carlton). 23(9):821-829, 2018
  9. Sogawa Y, Nagasu H, Itano S, Kidokoro K, Taniguchi S, Takahashi M, Kadoya H, Satoh M, Sasaki T, Kashihara N: The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice. PLoS One. 13(10):e0203823, 2018
  10. Node K, Kishi T, Tanaka A, Itoh H, Rakugi H, Ohya Y, Miura K, Okamura T, Ishimitsu T, Ichihara A, Ito M, Ohishi M, Ohkubo T, Kai H, Kashihara N, Kario K, Saitoh S, Tsuchihashi T, Nakamura S, Nishiyama A, Hasebe N, Higaki J, Tamura K, Kawano Y, Yatabe T, Ito S:JSH Future Plan Working Group and Executive Board Members. The Japanese Society of Hypertension-Digest of plan for the future. Hypertens Res. 41(12):989-990, 2018

2017年

  1. . Colchicine attenuates renal fibrosis in a murine unilateral ureteral obstruction model. Mol Med Rep. 15(6):4169-75, 2017
  2. Nishimura H, Yaoita E, Nameta M, Yamaguchi K, Sato M, Ihoriya C, Zhao L, Kawachi H, Sasaki T, Ikezumi Y, Ouchi Y, Kashihara N, Yamamoto T. Restricted nutrition-induced low birth weight, low number of nephrons and glomerular mesangium injury in Japanese quail. J Dev Orig Health Dis. 8(3):287-300, 2017
  3. Tomita J, Mochizuki S, Fujimoto S, Kashihara N, Akasaka T, Tanimoto M, Yoshida K. Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. Biochem Biophys Res Commun. 484(4):740-5, 2017
  4. Nakamura K, Miura D, Saito Y, Yunoki K, Koyama Y, Satoh M, Kondo M, Osawa K, Hatipoglu OF, Miyoshi T, Yoshida M, Morita H, Ito H. Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice.PLoS One.12(8);e0181009, 2017
  5. Sogawa Y, Nagasu H, Iwase S, Ihoriya C, Itano S, Uchida A, Kidokoro K, Taniguchi S, Takahashi M, Satoh M, Sasaki T, Suzuki T, Yamamoto M, Horng T, Kashihara N. Infiltration of M1, but not M2, macrophages is impaired after unilateral ureter obstruction in Nrf2-deficient mice. Sci Rep.7(1);8801,2017

2016年

  1. Nagasu H, Satoh M, Kiyokage E, Kidokoro K, Toida K, Channon KM, Kanwar YS, Sasaki T, Kashihara N. Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic mice. Lab Invest. 96(1):25-36, 2016
  2. Namikoshi T, Harada K, Hatta H, Tokura T, Oshiro Y, Nishizaki T, Obata T, Mori M, Fueki T, Fujimoto S, Haruna Y, Kuwabara A, Yorimitsu D, Ihoriya C, Kadoya H, Itano S, Fujimoto Y, Komai N, Sasaki T, Kashihara N. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.Clin Exp Nephrol.20(1):134-42, 2016
  3. Kidokoro K, Satoh M, Itano S, Kuwabara A, Sasaki T, Kashihara N. Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice.
    J Renin Angiotensin Aldosterone Syst. 17(2): on line, 2016
  4. Kadoya H, Uchida A, Kashihara N. A case of copper deficiency-induced pancytopenia with maintenance hemodialysis outpatient treated with polaprezinc. Ther Apher Dial. 20(4):422-3, 2016
  5. Kadoya H, Satoh M, Haruna Y, Sasaki T, Kashihara N. Klotho attenuates renal hypertrophy and glomerular injury in Ins2Akita diabetic mice. Clin Exp Nephrol. 20(5):671-8, 2016
  6. Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, Kamiya H, Ajioka M, Ishihara M, Dai K, Nanasato M, Sata M, Maemura K, Tomiyama H, Higashi Y, Kaku K, Yamada H, Matsuhisa M, Yamashita K, Bando YK, Kashihara N, Ueda S, Inoue T, Tanaka A, Node K; PROLOGUE Study Investigators. The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Med. 13(6):e1002051, 2016

2015年

  1. Combination Irbesartan/Amlodipine versus Irbesartan/Cilnidipine for Attenuation of Albuminuria in Rats with Streptozotocin-Induced Diabetic Nephropathy. Pharm Anal Acta. 6(5):369, 2015
  2. Kadoya H, Satoh M, Nagasu H, Sasaki T, Kashihara N;Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice. Clin Exp Nephrol.19(4):567-75, 2015
  3. Namikoshi T, Fujimoto S, Yorimitsu D, Ihoriya C, Fujimoto Y, Komai N, Sasaki T, Kashihara N. Relationship between vascular function indexes, renal arteriolosclerosis, and renal clinical outcomes in chronic kidney disease. Nephrology (Carlton). 20(9):585-90, 2015
  4. Kadoya H, Satoh M, Sasaki T, Taniguchi S, Takahashi M, Kashihara N. Excess aldosterone is a critical danger signal for inflammasome activation in the development of renal fibrosis in mice. FASEB J. 29(9):3899-910, 2015
  5. Yorimitsu D, Sasaki T, Horike H, Fueki T, Hujimoto S, Komai N, Satoh M, Kashihara N. Severe hyperkalemia following ileostomy not colostomy in a patient undergoing chronic hemodialysis. Kawasaki Med J. 41(2):65-69, 2015

2014年

  1. Angiotensin II Regulates Islet Microcirculation and Insulin Secretion in Mice.Microcirculation. 21(2):112-23, 2014
  2. Satoh M, Nagasu H, Haruna Y, Ihoriya C, Kadoya H, Sasaki T, Kashihara N. Hypertension promotes islet morphological changes with vascular injury on pre-diabetic status in SHRsp rats. Clin Exp Hypertens. 36(3):159-164, 2014
  3. Ihoriya C, Satoh M, Komai N, Sasaki T, Kashihara N. Nuclear factor erythroid 2-related factor 2 is activated by rosuvastatin via p21cip1 upregulation in endothelial cells. Biochem Pharmacol (Los Angel). 4(1):157, 2014

2013年

  1. Angiostatin production increases in response to decreased nitric oxide in aging rat kidney. Lab Invest. 93(3):334-43,2013
  2. Nishi Y, Satoh M, Nagasu H, Kadoya H, Ihoriya C, Kidokoro K, Sasaki T, Kashihara N. Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status. Kidney Int. 83(4):662-73,2013
  3. Satoh M, Ueta H, Tokura T, Sasaki T, Kashihara N. Erythropoietin-producing tubercle granuloma in a hemodialysis patient. BMC Nephrol. 14(1):91,2013
  4. Kidokoro K, Satoh M, Channon KM, Yada T, Sasaki T, Kashihara N. Maintenance of Endothelial Guanosine Triphosphate Cyclohydrolase I Ameliorates Diabetic Nephropathy.J Am Soc Nephrol. 24(7):1139-50,2013

2012年

  1. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Hypertens Res. 35(3):348-55,2012
  2. Nagasu H, Satoh M, Kidokoro K, Nishi Y, Channon KM, Sasaki T, Kashihara N. Endothelial dysfunction promotes the transition from compensatory renal hypertrophy to kidney injury after unilateral nephrectomy in mice. Am J Physiol Renal Physiol. 302(11):F1402-8,2012
  3. Kidokoro K, Satoh M, Nagasu H, Sakuta T, Kuwabara A, Yorimitsu D, Nishi Y, Tomita N, Sasaki T, Kashihara N. Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change. Kidney Blood Press Res. 35(6):549-57,2012
  4. Yorimitsu D, Satoh M, Koremoto M, Haruna Y, Nagasu H, Kuwabara A, Sasaki T, Kashihara N. Establishment of a blood purification system for renal failure rats using small-size dialyzer membranes. Ther Apher Dial. 16(6):566-72,2012
  5. Satoh M, Nagasu H, MoritaY, Yamaguchi TP, Kanwar YS, Kashihara N. Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling.Am J Physiol Renal Physiol. 303(12):F1641-51,2012

2011年

  1. Comparison of Combination Therapy of Olmesartan plus Azelnidipine or Hydrochlorothiazide on Renal and Vascular Damage in SHR/NDmcr-cp Rats.Kidney Blood Press Res. 34(2):87-96,2011
  2. Satoh M, Fujimoto S, Horike H, Ozeki M, Nagasu H, Tomita N, Sasaki T, Kashihara N. Mitochondrial damage-induced impairment of angiogenesis in the aging rat kidney. Lab Invest. 91(2):190-202,2011
  3. Nagasu H, Satoh M, Kuwabara A, Yorimitsu D, Kidokoro K, Nishi Y, Tomita N, Sasaki T, Kashihara N. Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals.　Biochem Biophys Res Commun. 407(1):39-43,2011
  4. Tokura T, Itano S, Kobayashi S, Kuwabara A, Fujimoto S, Horike H, Satoh M, Komai N, Tomita N, Matsunaga A, Saito T,  Sasaki T, Kashihara N. A Novel Mutation ApoE2 Kurashiki (R158P) in a Patient with Lipoprotein Glomerulopathy. J Atheroscler Thromb. 18(6):536-41,2011

2010年

  1. Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats. Hypertens Res. 33(2):135-42,2010
  2. Satoh M, Kobayashi S, Kuwabara A, Tomita N, Sasaki T, Kashihara N. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats.
  3. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant. 25(9):2889-98,2010
  4. Sakuta T, Morita Y, Satoh M, David A. Fox, Kashihara N. Involvment of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis. Arthritis Rheum. 62(5):1319-28,2010
  5. Clear correlation of tetrahydrobiopterin with nitric oxide bioavailability in continuous ambulatory peritoneal dialysis. Blood Purif. 30(2):96-7, 2010
  6. Kuwabara A, Satoh M, Tomita N, Sasaki T, Kashihara N. Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats. Diabetologia. 53(9):2056-65,2010
  7. Nishi Y, Namikoshi T, Sasaki T, Tokura T, Nagasu H, Nakanishi H, Kozuka Y, Kashihara N. Histopathological manifestations of membranoproliferative glomerulonephritis and glomerular expression of plasmalemmal vesicle-associated protein-1 in a patient with polycythemia vera. Clinical Nephrology. 74(5):393-8,2010